99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Status Recruiting

Clinical Trial Summary

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To define the biodistribution of 99mTc-based PSMA imaging and surgery agent (99mTc-PSMA-I&S) in normal and malignant tissues of patients with prostate cancer (PCa) with histopathology validation, when available. SECONDARY OBJECTIVES: I. To correlate the 99mTc-PSMA-I&S accumulation within tumor lesions observed by in-vivo single-photon emission computed tomography (SPECT), ex-vivo gamma measurements and level of prostate-specific membrane antigen (PSMA) expression quantified by histopathology, when available. II. To define the best time-point for radio-guided surgery (RGS) with the highest tumor-to-background ratio following 99mTc-PSMA-I&S administration. OUTLINE: The first 5 patients receive an initial dose of 99mTc-PSMA-I&S intravenously (IV) followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&S IV before surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04857502
Study type	Interventional
Source	Jonsson Comprehensive Cancer Center
Contact	Deepu Varughese
Phone	310-206-7372
Email	DVarughese@mednet.ucla.edu
Status	Recruiting
Phase	Early Phase 1
Start date	April 27, 2021
Completion date	June 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04457232` - Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation	Phase 1
Active, not recruiting	`NCT03661437` - Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy	Early Phase 1
Completed	`NCT02337465` - KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer	N/A
Completed	`NCT03013413` - Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy	N/A
Recruiting	`NCT06037863` - Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial	N/A
Active, not recruiting	`NCT03580499` - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy	N/A
Completed	`NCT03326440` - Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer	N/A
Recruiting	`NCT04597359` - To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring	Phase 2
Active, not recruiting	`NCT03263650` - Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC	Phase 2
Active, not recruiting	`NCT04600336` - Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer	Phase 2
Active, not recruiting	`NCT04299620` - Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy	N/A
Completed	`NCT04976257` - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion	Early Phase 1
Completed	`NCT02957981` - The Genetic Education for Men Trial: Web-Based Education vs. Standard Care	N/A
Withdrawn	`NCT03408561` - Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer	N/A
Enrolling by invitation	`NCT06347809` - DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Enrolling by invitation	`NCT04254133` - Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
Recruiting	`NCT05519878` - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers	N/A
Recruiting	`NCT02994758` - Development of Diagnostics and Treatment of Urological Cancers	N/A
Completed	`NCT01497431` - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants	Phase 1
Active, not recruiting	`NCT00002540` - Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)	N/A